Klebsiella Pneumoniae Infections - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 88 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Klebsiella Pneumoniae Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Klebsiella Pneumoniae Infections - Pipeline Review, H2 2014', provides an overview of the Klebsiella Pneumoniae Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Klebsiella Pneumoniae Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Klebsiella Pneumoniae Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Klebsiella Pneumoniae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Klebsiella Pneumoniae Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Klebsiella Pneumoniae Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Klebsiella Pneumoniae Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Klebsiella Pneumoniae Infections Overview 9
Therapeutics Development 10
Pipeline Products for Klebsiella Pneumoniae Infections - Overview 10
Pipeline Products for Klebsiella Pneumoniae Infections - Comparative Analysis 11
Klebsiella Pneumoniae Infections - Therapeutics under Development by Companies 12
Klebsiella Pneumoniae Infections - Therapeutics under Investigation by Universities/Institutes 15
Klebsiella Pneumoniae Infections - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Klebsiella Pneumoniae Infections - Products under Development by Companies 18
Klebsiella Pneumoniae Infections - Products under Investigation by Universities/Institutes 19
Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development 20
Sumitomo Dainippon Pharma Co., Ltd. 20
Melinta Therapeutics, Inc 21
Cubist Pharmaceuticals, Inc. 22
Pfizer Inc. 23
Soligenix, Inc. 24
Debiopharm International S.A. 25
Theraclone Sciences, Inc. 26
Syntiron LLC 27
FOB Synthesis, Inc. 28
Cellceutix Corporation 29
Phico Therapeutics Ltd. 30
Trana Discovery, Inc. 31
Northern Antibiotics Oy 32
Nosopharm SAS 33
Arsanis Biosciences GmbH 34
Klebsiella Pneumoniae Infections - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 41
Drug Profiles 43
CB-618 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
RX-04 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
RX-05 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecule for Gram-Negative Nonsocomial Infections - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CB-027 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
SM-295291 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
NAB-739 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SM-369926 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SGX-942 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
NOSO-95 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Antimicrobial Compounds for Bacterial Infections - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NAB-741 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
NAB-7061 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Monoclonal Antibodies for Klebsiella Pneumoniae Infections - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
IBN-1 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PMBN-fMLF - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PMEN-fMLF - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
FSI-1671 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
FSI-1686 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CTIX-1278 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
klebsiella pneumoniae vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
PT-3.X - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
MVX-506 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Monoclonal Antibody for Klebsiella Pneumoniae Infections - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
NVN-4428 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Debio-1454 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Klebsiella Pneumoniae Infections - Recent Pipeline Updates 75
Klebsiella Pneumoniae Infections - Dormant Projects 78
Klebsiella Pneumoniae Infections - Discontinued Products 79
Klebsiella Pneumoniae Infections - Product Development Milestones 80
Featured News & Press Releases 80
Feb 26, 2014: Venus bags marketing approvar from Myanmar for its fragship product Erores 80
Apr 29, 2013: Basilea Pharma To Present Data On Sulfactam Antibiotic BAL30072 At ECCMID 2013 80
Sep 12, 2012: Phico Therapeutics Achieves Developmental Milestone In Fight Against Multidrug Resistant Bacteria Enzyme NDM-1 81
Sep 12, 2012: Merck Announces Presentation Of Scientific Data On Investigational Agent MK-7655 At 52nd Annual ICAAC 82
Sep 12, 2012: Rib-X Pharma Presents Preclinical Studies With New Classes Of RX-04 Antibiotic Compounds At ICAAC 84
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-027 At ICAAC 2012 85
Sep 05, 2012: Rib-X Pharma To Present Data On RX-04 Program At ICAAC 2012 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 88
Disclaimer 88

List of Tables
Number of Products under Development for Klebsiella Pneumoniae Infections, H2 2014 10
Number of Products under Development for Klebsiella Pneumoniae Infections - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Development by Companies, H2 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Klebsiella Pneumoniae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 20
Klebsiella Pneumoniae Infections - Pipeline by Melinta Therapeutics, Inc, H2 2014 21
Klebsiella Pneumoniae Infections - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 22
Klebsiella Pneumoniae Infections - Pipeline by Pfizer Inc., H2 2014 23
Klebsiella Pneumoniae Infections - Pipeline by Soligenix, Inc., H2 2014 24
Klebsiella Pneumoniae Infections - Pipeline by Debiopharm International S.A., H2 2014 25
Klebsiella Pneumoniae Infections - Pipeline by Theraclone Sciences, Inc., H2 2014 26
Klebsiella Pneumoniae Infections - Pipeline by Syntiron LLC, H2 2014 27
Klebsiella Pneumoniae Infections - Pipeline by FOB Synthesis, Inc., H2 2014 28
Klebsiella Pneumoniae Infections - Pipeline by Cellceutix Corporation, H2 2014 29
Klebsiella Pneumoniae Infections - Pipeline by Phico Therapeutics Ltd., H2 2014 30
Klebsiella Pneumoniae Infections - Pipeline by Trana Discovery, Inc., H2 2014 31
Klebsiella Pneumoniae Infections - Pipeline by Northern Antibiotics Oy, H2 2014 32
Klebsiella Pneumoniae Infections - Pipeline by Nosopharm SAS, H2 2014 33
Klebsiella Pneumoniae Infections - Pipeline by Arsanis Biosciences GmbH, H2 2014 34
Assessment by Monotherapy Products, H2 2014 35
Number of Products by Stage and Target, H2 2014 37
Number of Products by Stage and Mechanism of Action, H2 2014 39
Number of Products by Stage and Route of Administration, H2 2014 40
Number of Products by Stage and Molecule Type, H2 2014 42
Klebsiella Pneumoniae Infections Therapeutics - Recent Pipeline Updates, H2 2014 75
Klebsiella Pneumoniae Infections - Dormant Projects, H2 2014 78
Klebsiella Pneumoniae Infections - Discontinued Products, H2 2014 79